Spark Streamlines Research Pipeline

Spark Therapeutics, the gene therapy division of Roche, has announced the termination of several early-stage projects to speed up its pipeline development. This strategic decision also involves "organizational changes," which will affect the employment of a certain number of staff members. "We began to notify employees this week about any impact to their employment," the company stated.

Spark Therapeutics made history in late 2017 when it secured the first-ever FDA approval for a gene therapy. This therapy, named Luxturna (voretigene neparvovec-rzyl), is designed to treat a rare genetic form of blindness. Following this groundbreaking achievement, Roche acquired the biotech company for $4.8 billion in 2019.

The company’s research pipeline, includes projects targeting Stargardt disease, lysosomal storage disorders, and neurodegenerative diseases. These areas represent significant unmet medical needs and potential therapeutic advancements.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!